THE ROLE OF LIRAGLUTIDE TREATMENT ON WEIGHT LOSS FOR PATIENTS WITH SUBOPTIMAL INITIAL RESPONSE OR WEIGHT REGAIN AFTER BARIATRIC SURGERY

Background:Glucagon-like peptide-1 receptor agonists (GLP1-RAs) are a form of incretin-based therapy that treats hyperglycemia and, in some situations, cardiovascular risk in persons with type 2 diabetes. Aim:Is to determine the efficacy and safety of prescribing GLP1-RAs for patients who had suboptimal initial response or regained weight after bariatric surgery.PatientsandMethodes:A retrospective cross-sectional study was done from the 1st of February /2023 to the 1st of August/2024 in Al-Sadr Teaching Hospital, Iraq. Clinical data including (age, sex, height, weight, BMI, any chronic disease, time of bariatric surgery) were collected. Eighty-six patients were divided into two groups for the study. Seventy-two patients in the first group who gained weight after the weight nadir at least a year after bariatric surgery, 14 patients in the second group who had suboptimal initial response 12 months following bariatric surgery. Liraglutide was administered for 4 -8 months for both groups.Results:The study revealed that 70.9% of patients from both groups responded to the GLP1 therapy, with slightly higher responsiveness in the weight regain group (73.61%) than in the Suboptimal initial response group (57.14%), the difference was not statistically significant (p = 0.358).Both groups significantly reduced their BMI, with a mean pre-treatment to post-treatment BMI difference of 6.02 ±1.97 in the Suboptimal initial response group and 6.06 ± 1.21 in the weight regain group. However, there was no statistically significant difference between the two groups (p = 0.18).Both groups lost weight, with the Suboptimal initial response group losing 10.9% of their weight from pretreatment to post-treatment and the weight regain group gaining 11.3%. There was no statistically significant difference between the two groups (p = 0.112).Conclusion:We discovered that liraglutide 3.0 mg helped post-bariatric surgery patients who had either too much weight gain or insufficient weight loss.

Authors

Institutions

Publication Details

Journal
Basrah Journal of Surgery
Published
2025-12-20
DOI
https://doi.org/10.33762/basjsurg.2025.163362.1137
Primary Topic
Bariatric Surgery and Outcomes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

THE ROLE OF LIRAGLUTIDE TREATMENT ON WEIGHT LOSS FOR PATIENTS WITH SUBOPTIMAL INITIAL RESPONSE OR WEIGHT REGAIN AFTER BARIATRIC SURGERY

Aaseef Mohammed, Issam Merdan
Basrah Journal of Surgery
Bariatric Surgery and Outcomes
article

THE ROLE OF LIRAGLUTIDE TREATMENT ON WEIGHT LOSS FOR PATIENTS WITH SUBOPTIMAL INITIAL RESPONSE OR WEIGHT REGAIN AFTER BARIATRIC SURGERY

Aaseef Mohammed, Issam Merdan
article en

Abstract

Background:Glucagon-like peptide-1 receptor agonists (GLP1-RAs) are a form of incretin-based therapy that treats hyperglycemia and, in some situations, cardiovascular risk in persons with type 2 diabetes. Aim:Is to determine the efficacy and safety of prescribing GLP1-RAs for patients who had suboptimal initial response or regained weight after bariatric surgery.PatientsandMethodes:A retrospective cross-sectional study was done from the 1st of February /2023 to the 1st of August/2024 in Al-Sadr Teaching Hospital, Iraq. Clinical data including (age, sex, height, weight, BMI, any chronic disease, time of bariatric surgery) were collected. Eighty-six patients were divided into two groups for the study. Seventy-two patients in the first group who gained weight after the weight nadir at least a year after bariatric surgery, 14 patients in the second group who had suboptimal initial response 12 months following bariatric surgery. Liraglutide was administered for 4 -8 months for both groups.Results:The study revealed that 70.9% of patients from both groups responded to the GLP1 therapy, with slightly higher responsiveness in the weight regain group (73.61%) than in the Suboptimal initial response group (57.14%), the difference was not statistically significant (p = 0.358).Both groups significantly reduced their BMI, with a mean pre-treatment to post-treatment BMI difference of 6.02 ±1.97 in the Suboptimal initial response group and 6.06 ± 1.21 in the weight regain group. However, there was no statistically significant difference between the two groups (p = 0.18).Both groups lost weight, with the Suboptimal initial response group losing 10.9% of their weight from pretreatment to post-treatment and the weight regain group gaining 11.3%. There was no statistically significant difference between the two groups (p = 0.112).Conclusion:We discovered that liraglutide 3.0 mg helped post-bariatric surgery patients who had either too much weight gain or insufficient weight loss.

Basrah Journal of SurgeryVol. 0(0)
University of Basrah (IQ)
Good health and well-being
Openalex Percentile: Top 28%
Bariatric Surgery and Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

THE ROLE OF LIRAGLUTIDE TREATMENT ON WEIGHT LOSS FOR PATIENTS WITH SUBOPTIMAL INITIAL RESPONSE OR WEIGHT REGAIN AFTER BARIATRIC SURGERY — Aaseef Mohammed, Issam Merdan · Basrah Journal of Surgery (2025) | TGRS Research Map | TGRS